Ethyl-EPA
Showing 1 - 25 of 432
Bipolar Disorder Trial in New York (Ethyl Eicosapentaenoic Acid)
Withdrawn
- Bipolar Disorder
- Ethyl Eicosapentaenoic Acid
-
New York, New YorkNew York State Psychiatric Institute/Columbia University Medical
Oct 12, 2022
Diabetes, Non-Insulin-Dependent, Hypertriglyceridemia Trial in Baton Rouge (Metformin Eicosapentaenoate, Metformin HCl and
Completed
- Diabetes Mellitus, Non-Insulin-Dependent
- Hypertriglyceridemia
- Metformin Eicosapentaenoate
- Metformin HCl and Vascepa
-
Baton Rouge, LouisianaPennington Biomedical Research Center
Apr 25, 2022
Liver Metastasis, Colon Cancer Trial in United Kingdom (Icosapent Ethyl, Placebo)
Recruiting
- Liver Metastasis
- Colon Cancer
- Icosapent Ethyl
- Placebo
-
Oxford, Oxfordshire, United Kingdom
- +12 more
Nov 7, 2022
COVID19 Trial in Rosario (Icosapent ethyl (IPE), Placebo)
Completed
- COVID19
- Icosapent ethyl (IPE)
- Placebo
-
Rosario, Santa Fe, ArgentinaInstituto de Investigaciones Clínicas - Rosario
Sep 10, 2021
Type 2 Diabetes, Coronary Artery Disease Trial in Boston (Icosapent ethyl)
Terminated
- Type 2 Diabetes
- Coronary Artery Disease
- Icosapent ethyl
-
Boston, MassachusettsBrigham and Women's Hospital
Feb 22, 2022
Healthy Adults Trial in Rimouski (MAG-EPA/MAG-DHA, TG-EPA/TG-DHA, EE-EPA/EE-DHA)
Completed
- Healthy Adults
- MAG-EPA/MAG-DHA
- +2 more
-
Rimouski, Quebec, CanadaSCF pharma
Apr 28, 2021
Healthy Trial in Sherbrooke (omega-3 fatty acid supplementation, corn/soybean oil )
Completed
- Healthy
- omega-3 fatty acid supplementation
- corn/soybean oil placebo
-
Sherbrooke, Quebec, CanadaPL Léveillé
May 6, 2020
Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver
Recruiting
- Colon Cancer Liver Metastasis
- Icosapent Ethyl Oral Capsule
- Placebo
-
Leeds, United Kingdom
- +1 more
Sep 27, 2021
Diabetes Type 2, Hypertriglyceridemia, Diabetes Trial in Ioannina (EPAVasc, Corn Oil)
Not yet recruiting
- Diabetes Type 2
- +2 more
- EPAVasc
- Corn Oil
-
Ioannina, Epirus, GreeceAtherothrombosis Research Centre / Laboratory of Biochemistry, U
Nov 13, 2023
Atherosclerosis, Low-density Lipoproteins Aggregation Susceptibility, Low-density Lipoprotein Lipid Composition Trial in
Unknown status
- Atherosclerosis
- +3 more
- Ethyl-Eicosapentaenoic Acid (E-EPA)
-
Helsinki, FinlandWihuri Research Institute
Nov 15, 2019
Lipid Disorder, Triglycerides High, Dyslipidemias Trial in Philadelphia (Icosapent Ethyl 1000 MG [Vascepa])
Completed
- Lipid Disorder
- +2 more
- Icosapent Ethyl 1000 MG [Vascepa]
-
Philadelphia, PennsylvaniaPerelman School of Medicine at the University of Pennsylvania
Oct 15, 2021
Cardiovascular Diseases Trial in Worldwide (AMR101, Placebo, Statin therapy)
Cardiovascular Diseases, Cardiovascular Risk Factor, Triglycerides High Trial in Canada (Icosapent Ethyl 1000 MG Oral Capsule
Recruiting
- Cardiovascular Diseases
- +3 more
- Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
-
North York, Ontario, Canada
- +3 more
Nov 7, 2022
Colorectal Adenoma, Colorectal Cancer, Endoscopic Surgery Trial in Boston (AMR101)
Completed
- Colorectal Adenoma
- +4 more
-
Boston, MassachusettsMassachusetts General Hospital
Nov 18, 2022
Breast Cancer Trial in Kansas City (Omega-3 Fatty Acids, Placebo Capsule, Diet and Exercise)
Completed
- Breast Cancer
- Omega-3 Fatty Acids
- +2 more
-
Kansas City, KansasUniversity of Kansas Medical Center, Breast Cancer Prevention Ce
Jan 6, 2022
Optimal Gastrointestinal Absorption of Omega-3 Trial in Brisbane (Product 1 - AquaCelle Fish Oil Triglyceride, Product 2 -
Not yet recruiting
- Optimal Gastrointestinal Absorption of Omega-3
- Product 1 - AquaCelle Fish Oil Triglyceride
- +2 more
-
Brisbane, Queensland, AustraliaRDC Global Pty Ltd
Aug 8, 2022
Alzheimer's Disease Trial in Madison (icosapent ethyl (IPE), gel cap )
Active, not recruiting
- Alzheimer's Disease
- icosapent ethyl (IPE)
- gel cap placebo
-
Madison, WisconsinWilliam S. Middleton Memorial Veterans Hospital, Madison, WI
Jul 23, 2021
Absorption, Pharmacokinetics Trial in Esslingen (PL+ omega 3 fatty acids, FO EE fatty acids)
Active, not recruiting
- Absorption
- Pharmacokinetics
- PL+ omega 3 fatty acids
- FO EE fatty acids
-
Esslingen, GermanyBioTeSys GmbH
Jan 31, 2023
Dyslipidemias, Atherosclerosis, Diabetes, Type 2 Trial (Omega 3-Atorvastatin, Atorvastatin-Ezetimibe)
Recruiting
- Dyslipidemias
- +2 more
- Omega 3-Atorvastatin
- Atorvastatin-Ezetimibe
-
Seongnam, Gyeonggi, Korea, Republic ofSNUBH
Oct 1, 2022
Breast Cancer, Ovarian Tumor, Pain Trial in Albuquerque (Omega-3 fatty acid, Placebo, Paclitaxel)
Completed
- Breast Cancer
- +2 more
- Omega-3 fatty acid
- +2 more
-
Albuquerque, New Mexico
- +1 more
Oct 4, 2022
Healthy Trial in Sherbrooke (Omega-3 + vitamin K2 (monoacylglycerol form), Omega-3 + vitamin K2 (ethyl ester))
Completed
- Healthy
- Omega-3 + vitamin K2 (monoacylglycerol form)
- Omega-3 + vitamin K2 (ethyl ester)
-
Sherbrooke, Quebec, CanadaCentre de Recherche sur le Vieillissement
May 8, 2020
Healthy Trial in Overland Park (Rodatristat Ethyl, Moxifloxacin, Placebo for Rodatristat)
Recruiting
- Healthy
- Rodatristat Ethyl
- +3 more
-
Overland Park, KansasAltasciences Clinical Kansas, Inc.
Jul 5, 2023
Physical Activity Trial (Enhance Physical Activity (EPA))
Not yet recruiting
- Physical Activity
- Enhance Physical Activity (EPA)
- (no location specified)
Jan 18, 2023
Locally Advanced Neuroendocrine Tumor, Metastatic Neuroendocrine Tumor Trial in Houston (Placebo Administration, Questionnaire
Recruiting
- Locally Advanced Neuroendocrine Neoplasm
- Metastatic Neuroendocrine Neoplasm
- Placebo Administration
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2023
Inflammation; Skin, Resolution, Blister Trial in Boston (Lovaza, Cantharone, Phlebotomy)
Completed
- Inflammation; Skin
- +2 more
- Lovaza
- +2 more
-
Boston, MassachusettsBrigham and Women's Hospital
May 25, 2022